First Time Loading...

Ascendis Pharma A/S
NASDAQ:ASND

Watchlist Manager
Ascendis Pharma A/S Logo
Ascendis Pharma A/S
NASDAQ:ASND
Watchlist
Price: 151.17 USD 1.84% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. [ Read More ]

The intrinsic value of one ASND stock under the Base Case scenario is 149.35 USD. Compared to the current market price of 151.17 USD, Ascendis Pharma A/S is Overvalued by 1%.

Key Points:
ASND Intrinsic Value
Base Case
149.35 USD
Overvaluation 1%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Ascendis Pharma A/S

Backtest ASND Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ASND stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Ascendis Eyes Enhanced Market Penetration
2023-Q3 Earnings Call

Ascendis Eyes Enhanced Market Penetration

Ascendis Pharma posted a total revenue of €48 million for Q3 2023, almost entirely driven by its flagship product SKYTROFA, which generated €47 million. The firm's growth in the U.S. was significant, achieving low double-digit penetration among pediatric growth hormone deficiency (GHD) patients. To bolster its portfolio, Ascendis released interim results from ongoing clinical trials and increased its 2023 SKYTROFA revenue forecast to €170-175 million. Key upcoming milestones include a potential label expansion for SKYTROFA, pending Phase III data, and a resubmission of its NDA for TransCon PTH for hypoparathyroidism, with a European Commission decision expected soon.

Financials

Balance Sheet Decomposition
Ascendis Pharma A/S

Current Assets 702.7m
Cash & Short-Term Investments 399.4m
Receivables 55.8m
Other Current Assets 247.5m
Non-Current Assets 122.9m
Long-Term Investments 5.7m
PP&E 110.6m
Intangibles 4.4m
Other Non-Current Assets 2.1m
Current Liabilities 197.3m
Accounts Payable 94.6m
Other Current Liabilities 102.8m
Non-Current Liabilities 773.9m
Long-Term Debt 618.9m
Other Non-Current Liabilities 155.1m
Efficiency

Earnings Waterfall
Ascendis Pharma A/S

Revenue
266.7m EUR
Cost of Revenue
-44.4m EUR
Gross Profit
222.3m EUR
Operating Expenses
-670m EUR
Operating Income
-447.7m EUR
Other Expenses
-33.7m EUR
Net Income
-481.4m EUR

Free Cash Flow Analysis
Ascendis Pharma A/S

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

ASND Profitability Score
Profitability Due Diligence

Ascendis Pharma A/S's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
Positive Gross Profit
Exceptional 1-Year Revenue Growth
33/100
Profitability
Score

Ascendis Pharma A/S's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

ASND Solvency Score
Solvency Due Diligence

Ascendis Pharma A/S's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Positive Net Debt
Long-Term Solvency
41/100
Solvency
Score

Ascendis Pharma A/S's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ASND Price Targets Summary
Ascendis Pharma A/S

Wall Street analysts forecast ASND stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ASND is 175.64 USD with a low forecast of 117.16 USD and a high forecast of 236.25 USD.

Lowest
Price Target
117.16 USD
22% Downside
Average
Price Target
175.64 USD
16% Upside
Highest
Price Target
236.25 USD
56% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

ASND Price
Ascendis Pharma A/S

1M 1M
+2%
6M 6M
+61%
1Y 1Y
+37%
3Y 3Y
+17%
5Y 5Y
+28%
10Y 10Y
+703%
Annual Price Range
151.17
52w Low
69.96
52w High
159.4
Price Metrics
Average Annual Return 2.03%
Standard Deviation of Annual Returns 19.35%
Max Drawdown -62%
Shares Statistics
Market Capitalization 8.7B USD
Shares Outstanding 56 614 400
Percentage of Shares Shorted 7.63%

ASND Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Ascendis Pharma A/S Logo
Ascendis Pharma A/S

Country

Denmark

Industry

Biotechnology

Market Cap

8.7B USD

Dividend Yield

0%

Description

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. The firm utilizes its TransCon technologies for treatment, which can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs. The firm is headquartered in Copenhagen, Denmark with offices in Heidelberg, Germany and Palo Alto, California.

Contact

Hellerup
Tuborg Boulevard 12
+4570222244.0
https://ascendispharma.dk/

IPO

2015-01-28

Employees

639

Officers

President, CEO, Member of Executive Board & Executive Director
Mr. Jan Moller Mikkelsen
CFO, Executive VP & Member of Executive Board
Mr. Scott T. Smith
Executive VP, Chief Administrative Officer & Member of the Executive Board
Ms. Lotte Sonderbjerg
Executive VP, Chief Legal Officer & Member of the Executive Board
Mr. Michael Wolff Jensen L.L.M.
VP of Finance & Principal Accounting Officer
Mr. Peter Rasmussen
Senior Director of Investor Relations
Mr. Timothy J. Lee
Show More
Executive Vice President of Product Supply & Quality
Mr. Flemming Steen Jensen
Executive VP and Head of Research & Product Development
Dr. Kennett Sprogoe Ph.D.
Executive VP & Head of Clinical Development for Oncology
Dr. Stina Singel M.D., Ph.D.
Head of U.S. Commercial of Endocrinology
Mr. Joseph Kelly
Show Less

See Also

Discover More
What is the Intrinsic Value of one ASND stock?

The intrinsic value of one ASND stock under the Base Case scenario is 149.35 USD.

Is ASND stock undervalued or overvalued?

Compared to the current market price of 151.17 USD, Ascendis Pharma A/S is Overvalued by 1%.